Mullerian adenosarcoma of the uterus with MASO: a case report of cervical adenosarcoma in a young female that never had sexual behavior.


Journal

BMC women's health
ISSN: 1472-6874
Titre abrégé: BMC Womens Health
Pays: England
ID NLM: 101088690

Informations de publication

Date de publication:
23 May 2024
Historique:
received: 03 08 2023
accepted: 09 05 2024
medline: 24 5 2024
pubmed: 24 5 2024
entrez: 23 5 2024
Statut: epublish

Résumé

Cervical mullerian adenosarcoma is a rare uterine sarcoma, especially in young women. Its pathological features are low-grade malignant tumors with bidirectional differentiation, and the degree of malignancy is similar to that of low-grade endometrial stromal sarcoma. This paper reports the case of a young asexual patient who has been closely followed up after tumor resection and has not had any recurrences. A 20-year-old, young asexual woman was diagnosed with cervical mullerian adenosarcoma with sarcomatous overgrowth (MASO). Cervical tumor resection was performed after admission, and the resection margin was negative. After the operation, she refused to undergo secondary surgery due to fertility requirements and did not receive adjuvant treatment. The patient was closely followed up after the operation and has not yet relapsed. A young woman with cervical MASO did not receive adjuvant treatment after cervical tumor resection. For women with fertility requirements, close follow-ups should be conducted after the operation to guard against tumor recurrence and radical tumor resection should be performed as early as possible after the patient no longer requires their fertility.

Sections du résumé

BACKGROUND BACKGROUND
Cervical mullerian adenosarcoma is a rare uterine sarcoma, especially in young women. Its pathological features are low-grade malignant tumors with bidirectional differentiation, and the degree of malignancy is similar to that of low-grade endometrial stromal sarcoma. This paper reports the case of a young asexual patient who has been closely followed up after tumor resection and has not had any recurrences.
CASE PRESENTATION METHODS
A 20-year-old, young asexual woman was diagnosed with cervical mullerian adenosarcoma with sarcomatous overgrowth (MASO). Cervical tumor resection was performed after admission, and the resection margin was negative. After the operation, she refused to undergo secondary surgery due to fertility requirements and did not receive adjuvant treatment. The patient was closely followed up after the operation and has not yet relapsed.
CONCLUSION CONCLUSIONS
A young woman with cervical MASO did not receive adjuvant treatment after cervical tumor resection. For women with fertility requirements, close follow-ups should be conducted after the operation to guard against tumor recurrence and radical tumor resection should be performed as early as possible after the patient no longer requires their fertility.

Identifiants

pubmed: 38783282
doi: 10.1186/s12905-024-03140-w
pii: 10.1186/s12905-024-03140-w
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

308

Subventions

Organisme : National Natural Science Foundation of China
ID : 82160538

Informations de copyright

© 2024. The Author(s).

Références

Morales FDA, Medina RML, Trujillo LM, Beltrán MI, Dulcey IC. Müllerian adenosarcoma of the uterine cervix with sarcomatous overgrowth: a case report of aggressive disease in a young patient. Int J Surg Case Rep. 2016;27:155–61.
doi: 10.1016/j.ijscr.2016.08.044
García-Mendoza YI, Murguia-Perez M, Galván-Linares AI, et al. Case Report: Uterine Adenosarcoma with Sarcomatous overgrowth and malignant heterologous elements. Front Med (Lausanne). 2022;8:819141. Published 2022 Jan 10.
doi: 10.3389/fmed.2021.819141 pubmed: 35083260
Kudela E, Nachajova M, Balharek T, Gabonova E, Danko J. Mullerian adenosarcomas of the uterine cervix with sarcomatous overgrowth. Curr Probl Cancer. 2019;43(4):371–6.
doi: 10.1016/j.currproblcancer.2018.11.002 pubmed: 30522776
Goh C, Lin XH, Chin PS, Lim YK. Uterine preservation in a young patient with adenosarcoma of the uterus - case report and review of literature. Gynecol Oncol Rep. 2018;25:27–9. Published 2018 May 9.
doi: 10.1016/j.gore.2018.05.002 pubmed: 29977987 pmcid: 6030025
Liang J, Lin Z. FIGO cancer report 2018——interpretation of the diagnosis and treatment of uterine sarcomas. Chin J Practical Gynecol Obstet. 2018;34(12):1366–71. Chinese. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&dbname=CJFDLAST2019&filename=ZGSF201812018&uniplatform=NZKPT&v=umM-30p-IGb_GM6uW91wvfFF67NXFjTGATPzUzcSgiWYj_aek8rtwZ-g4W8yHJzL .
Taga S, Sawada M, Nagai A, Yamamoto D, Hayase R. A case of adenosarcoma of the uterus. Case Rep Obstet Gynecol. 2014;2014:342187.
pubmed: 24592340 pmcid: 3926369
Hoang L, Chiang S, Lee CH. Endometrial stromal sarcomas and related neoplasms: new developments and diagnostic considerations. Pathology. 2018;50(2):162–77.
doi: 10.1016/j.pathol.2017.11.086 pubmed: 29275929
Zhang Y, Li Y, Huang H, et al. Low-grade endometrial stromal sarcoma and uterine adenosarcoma: a comparison of clinical manifestations and outcomes. J Cancer. 2019;10(15):3352–60. Published 2019 Jun 5.
doi: 10.7150/jca.30691 pubmed: 31293638 pmcid: 6603426
Li H, Song M, Ma X, et al. Clinical analysis of 56 cases of Mullerian adenosarcoma. Chinese Journal of Practical Gynecology and Obstetrics. 2018;34(09):1047–1050. Chinese. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&dbname=CJFDLAST2018&filename=ZGSF201809030&uniplatform=NZKPT&v=umM-30p-IGbPN4V5PQADedF3qWHGKa1EPHHttOaZ1JQJ_2E8g6meNVFoPPAd7cbg
Wang B, Yang HD, Shi XH, Li H. Advanced uterine adenosarcoma with sarcomatous overgrowth in a young woman: a case report. Med (Baltim). 2019;98(47):e18119.
doi: 10.1097/MD.0000000000018119
Clement PB, Scully RE. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol. 1990;21(4):363–81.
doi: 10.1016/0046-8177(90)90198-E pubmed: 2156771
Mubeen A, Shahid M, Makary R. Post-radiation mullerian adenosarcoma with sarcomatous overgrowth: rare presentation of an uncommon malignancy. Pathologica. 2020;112(4):219–23.
doi: 10.32074/1591-951X-114 pubmed: 33393526 pmcid: 8183353
Nannini M, Dondi G, Santini D, De Leo A, Dei Tos AP, Zamagni C, Saponara M, Gatto L, Nigro C, Bertaccini P, Zompatori M, De Iaco P, Perrone AM, Perrone MA, Pantaleo MA. A single-centre experience on the management of Adenosarcoma: a successful report of an Integrated Medical and Surgical Approach. Clin Med Insights Oncol. 2018;12:1179554918782477.
doi: 10.1177/1179554918782477 pubmed: 29977120 pmcid: 6024524
Bogani G, Sopracordevole F, Ciavattini A, Vizza E, Vercellini P, Giannini A, Ghezzi F, Scambia G, Raspagliesi F, Di Donato V. Italian society of Colposcopy and Cervico-Vaginal Pathology (SICPCV); the investigators of the Italian HPV study group (iHPV study group). Duration of human papillomavirus persistence and its relationship with recurrent cervical dysplasia. Eur J Cancer Prev. 2023;32(6):525–32.
doi: 10.1097/CEJ.0000000000000822 pubmed: 37401466
Bogani G, Sopracordevole F, Ciavattini A, Vizza E, Vercellini P, Ghezzi F, Scambia G, Di Donato V, Giannini A, Raspagliesi F. HPV persistence after cervical surgical excision of high-grade cervical lesions. Cancer Cytopathol. 2023 Sep 25.
Mumba E, Ali H, Turton D, Cooper K, Grayson W. Human papillomaviruses do not play an aetiological role in Müllerian adenosarcomas of the uterine cervix. J Clin Pathol. 2008;61(9):1041–4.
doi: 10.1136/jcp.2008.056614 pubmed: 18552169
Omi M, Tonooka A, Chiba T, et al. Immunohistochemical markers and the clinical course of adenosarcoma: a series of seven cases. Diagn Pathol. 2020;15(1):119. Published 2020 Sep 24.
doi: 10.1186/s13000-020-01036-5 pubmed: 32972432 pmcid: 7513510
Wang Y, Liu AJ, Chen X, Song X. Prognosis-related clinicopathologic characteristics of FIGO stage I Müllerian adenosarcoma of uterus. Zhonghua Bing Li Xue Za Zhi. 2018;47(5):334–8.
pubmed: 29783798
Hodgson A, Amemiya Y, Seth A, Djordjevic B, Parra-Herran C. High-grade Müllerian Adenosarcoma: genomic and clinicopathologic characterization of a distinct neoplasm with prevalent TP53 pathway alterations and aggressive behavior. Am J Surg Pathol. 2017;41(11):1513–22.
doi: 10.1097/PAS.0000000000000907 pubmed: 28834809
Wu Y, Fan Y, Li J, et al. Unmarried asexual life female uterus mullerian ductal gland sarcoma: case report. Chin J Family Plann Gynecotokology. 2019;11(06):91–3. Chinese. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&dbname=CJFDLAST2019&filename=JHFC201906026&uniplatform=NZKPT&v=2K8Yz5RCR6gIp7bclE5U8yGFn154wd7bOfcpNXhmrcRsGgyt6NLTUAJUcs330DUf .
Seagle BL, Kanis M, Strohl AE, Shahabi S. Survival of women with mullerian adenosarcoma: a national cancer data base study. Gynecol Oncol. 2016;1433:636–41.
doi: 10.1016/j.ygyno.2016.10.013
Zhao Y. MRI features of uterine adenosarcoma. Journal of Nanchang University (Medical Sciences). 2021;61(01):52–56. Chinese. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&dbname=CJFDLAST2021&filename=JXYB202101012&uniplatform=NZKPT&v=ClbNsfAzITET85UPpXBiOm8kELy2MmN50gQye76E6Z53eZDmSFiWU-BD-7hZNn_N
Nathenson MJ, Ravi V, Fleming N, Wang WL, Conley A. Uterine adenosarcoma: a review. Curr Oncol Rep. 2016;18(11):68.
doi: 10.1007/s11912-016-0552-7 pubmed: 27718181
Zizolfi B, Foreste V, Di Spiezio Sardo A, Manzi A, Bifulco G, Carugno J. Fertility sparing management of uterine adenosarcoma: case report and literature review. Facts Views Vis Obgyn. 2021;12(4):315–8. Published 2021 Jan 8.
pubmed: 33575681 pmcid: 7863688
Mandato VD, Torricelli F, Mastrofilippo V, Valli R, Aguzzoli L, La Sala GB. Primary extra-uterine and extra-ovarian mullerian adenosarcoma: case report and literature review. BMC Cancer. 2018;181:134. Published 2018 Feb 5.
doi: 10.1186/s12885-018-4037-y
Xie L, Lin R, Lin Z. Interpretation of 2022 NCCN clinical practice guide for uterine tumors (version 1). Chin J Practical Gynecol Obstet. 2021;37(12):1227–33. Chinese. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&dbname=CJFDLAST2021&filename=ZGSF202101020&uniplatform=NZKPT&v=_uWLVYqiTg-a4l16tFTJWLKmR0rnrsmUM2hxKi0k0XXI6C_3c9kj5RbuhiZPWsRQ .
L’Heveder A, Jones BP, Saso S, et al. Conservative management of uterine adenosarcoma: lessons learned from 20 years of follow-up. Arch Gynecol Obstet. 2019;300(5):1383–9.
doi: 10.1007/s00404-019-05306-6 pubmed: 31584132 pmcid: 6814630
Schroeder B, Pollack SM, Jones RL. Systemic therapy in advanced uterine adenosarcoma with sarcomatous overgrowth. Gynecol Oncol. 2014;132(2):513.
doi: 10.1016/j.ygyno.2013.09.035 pubmed: 24333501
Pinto A, Howitt B. Uterine Adenosarcoma. Arch Pathol Lab Med. 2016;140(3):286–90.
doi: 10.5858/arpa.2014-0523-RS pubmed: 26927725
Tanner EJ, Toussaint T, Leitao MM Jr, et al. Management of uterine adenosarcomas with and without sarcomatous overgrowth. Gynecol Oncol. 2013;129(1):140–4.
doi: 10.1016/j.ygyno.2012.12.036 pubmed: 23283300
Monti M, D’Aniello D, Scopelliti A, Tibaldi V, Santangelo G, Colagiovanni V, Giannini A, DI Donato V, Palaia I, Perniola G, Giancotti A, Muzii L. Benedetti Panici P. Relationship between cervical excisional treatment for cervical intraepithelial neoplasia and obstetrical outcome. Minerva Obstet Gynecol. 2021;73(2):233–46.
doi: 10.23736/S2724-606X.20.04678-X pubmed: 33140628
Goh C, Lin XH, Chin PS, et al. Uterine preservation in a young patient with adenosarcoma of the uterus—case report and review of literature. Gynecol Oncol Rep. 2018;25:27–9.
doi: 10.1016/j.gore.2018.05.002 pubmed: 29977987 pmcid: 6030025
Fadavi P, Garousi M, Soltani S et al. The uterine adenosarcoma with postoperative residual in a woman treated by total abdominal hysterectomy/bilateral salpingo-oophorectomy: a case report and review of literature. Cancer Rep (Hoboken). 2023:e1891.
Wang Q, Sun S, Cai J, Yang L, Lv G, Yang Q. Uterine adenosarcoma: a case report and review of the literature. Am J Nucl Med Mol Imaging. 2023;13(2):70–6.
pubmed: 37214266 pmcid: 10193199
Dowding DD, Wayne LM, Guirguis AS. High grade uterine adenosarcoma with sarcomatous overgrowth in a young woman amenable to primary surgical reduction: a case study and literature review. Gynecol Oncol Rep. 2022;39:100920.
doi: 10.1016/j.gore.2021.100920 pubmed: 35036509
Nathenson MJ, Conley AP. Prognostic factors for uterine adenosarcoma: a review. Expert Rev Anticancer Ther. 2018;18(11):1093–100.
doi: 10.1080/14737140.2018.1518136 pubmed: 30169984
Carroll A, Ramirez PT, Westin SN, et al. Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence. Gynecol Oncol. 2014;135(3):455–61.
doi: 10.1016/j.ygyno.2014.10.022 pubmed: 25449308 pmcid: 4430193
Li JY, Mutlu L, Tymon-Rosario J, et al. Clinicopathologic characteristics and oncologic outcomes in adenosarcoma of gynecologic sites. Gynecol Oncol Rep. 2021;39:100913. Published 2021 Dec 20.
doi: 10.1016/j.gore.2021.100913 pubmed: 35005157 pmcid: 8715286
Wang J, Liu Q, Deng B, et al. Clinical analysis of 16 cases of uterine adenosarcoma. Chin J Family Plann Gynecotokology. 2019;11(12):78–82. Chinese. https://kns.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&dbname=CJFDLAST2020&filename=JHFC201912022&uniplatform=NZKPT&v=2K8Yz5RCR6j-KZis42TpI_0wm27dvE5mrn5aBx0niObfl05dJJZ1v2OvJD23A7NT .

Auteurs

Jia-Wei Chen (JW)

Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Zunyi Medical University, The intersection of Xinlong Avenue and Xinpu Avenue, Honghuagang District, Zunyi, Guizhou Province, 563000, China.

Ya-Jie Huang (YJ)

Department of Obstetrics and Gynecology, The Sixth People's Hospital of Chengdu, Chengdu, Sichuan, 610051, China.

Ling-Lu Wang (LL)

Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Zunyi Medical University, The intersection of Xinlong Avenue and Xinpu Avenue, Honghuagang District, Zunyi, Guizhou Province, 563000, China.

Jun-Jiang Liu (JJ)

Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Zunyi Medical University, The intersection of Xinlong Avenue and Xinpu Avenue, Honghuagang District, Zunyi, Guizhou Province, 563000, China.

Ming-Mei Shi (MM)

Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Zunyi Medical University, The intersection of Xinlong Avenue and Xinpu Avenue, Honghuagang District, Zunyi, Guizhou Province, 563000, China.

Na Li (N)

Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Zunyi Medical University, The intersection of Xinlong Avenue and Xinpu Avenue, Honghuagang District, Zunyi, Guizhou Province, 563000, China. foxlina2008@163.com.
Department of Obstetrics and Gynecology, The Sixth People's Hospital of Chengdu, Chengdu, Sichuan, 610051, China. foxlina2008@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH